advertisement
Abstract #20692 Published in IGR 10-1
Costs of vision impairment: Present and future issues
Keeffe JEExpert Review of Pharmacoeconomics and Outcomes Research 2007; 7: 523-527
There is no standard method for measuring costs of vision impairment. Examples are given of global estimates and from two industrialized countries, Australia and the USA. The comparisons between these countries illustrate how the differences in healthcare systems influence the contribution of direct and indirect costs to the total. Modeling of costs and outcomes (cost-effectiveness analysis) has illustrated the extraordinary benefit of programs to prevent vision loss and blindness. These data need to be used in advocacy for the funding of national Vision 2020: the Right to Sight programs.
Dr. J.E. Keeffe, Centre for Eye Research Australia, University of Melbourne, Locked Bag 8, East Melbourne, VIC 8002, Australia. jillek@unimelb.edu.au
Classification:
14 Costing studies; pharmacoeconomics
1.5 Glaucomas as cause of blindness (Part of: 1 General aspects)